{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:05:46Z","timestamp":1790604346855,"version":"4.1.0"},"reference-count":97,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2020,4,3]]},"DOI":"10.3233\/jpd-191856","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T11:18:06Z","timestamp":1582888686000},"page":"413-428","source":"Crossref","is-referenced-by-count":22,"title":["Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson\u2019s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer"],"prefix":"10.1177","volume":"10","author":[{"given":"Marie-Louise","family":"Zeissler","sequence":"first","affiliation":[{"name":"Applied Parkinson\u2019s Research Group, University of Plymouth, Faculty of Health: Medicine, Dentistry and Human Sciences, Plymouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Li","sequence":"additional","affiliation":[{"name":"Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, London, UK"},{"name":"Department of Uro-Neurology, National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, Queen Square, London, United Kingdom"},{"name":"MRC Clinical Trials Unit at UCL, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh K.B.","family":"Parmar","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille Buchholz","family":"Carroll","sequence":"additional","affiliation":[{"name":"Applied Parkinson\u2019s Research Group, University of Plymouth, Faculty of Health: Medicine, Dentistry and Human Sciences, Plymouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-191856_ref1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/mds.27302","article-title":"Short- and long-term cost and utilization of health care resources in Parkinson\u2019s disease in the UK","volume":"33","author":"Weir","year":"2018","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/mds.27063","article-title":"Projection of the prevalence of Parkinson\u2019s disease in coming decades: Revisited HHS Public Access","volume":"33","author":"Rossi","year":"2018","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref5","doi-asserted-by":"crossref","first-page":"20160180","DOI":"10.1042\/BSR20160180","article-title":"Bioinformatics in translational drug discovery","volume":"37","author":"Wooller","year":"2017","journal-title":"Biosci Rep"},{"key":"10.3233\/JPD-191856_ref6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/bab.1617","article-title":"Progress in biopharmaceutical development","volume":"65","author":"Kesik-Brodacka","year":"2018","journal-title":"Biotechnol Appl Biochem"},{"key":"10.3233\/JPD-191856_ref7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"Hollingsworth","year":"2018","journal-title":"Neuron"},{"key":"10.3233\/JPD-191856_ref8","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.drudis.2017.05.013","article-title":"Industrial medicinal chemistry insights: Neuroscience hit generation at Janssen","volume":"22","author":"Tresadern","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.3233\/JPD-191856_ref9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1248\/bpb.b15-00125","article-title":"Common mechanisms of onset of cancer and neurodegenerative diseases","volume":"38","author":"Ariga","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.3233\/JPD-191856_ref10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1872214810999160628105549","article-title":"Parkinson\u2019s disease, diabetes and cognitive impairment","volume":"10","author":"Ashraghi","year":"2016","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"10.3233\/JPD-191856_ref11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/ejn.14175","article-title":"The Linked Clinical Trials initiative (LCT) for Parkinson\u2019s disease","volume":"49","author":"Brundin","year":"2019","journal-title":"Eur J Neurosci"},{"key":"10.3233\/JPD-191856_ref12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JPD-139000","article-title":"Linked clinical trials \u2013 the development of new clinical learning studies in Parkinson\u2019s disease using screening of multiple prospective new treatments","volume":"3","author":"Brundin","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-191856_ref13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/01.STR.0000255227.96365.37","article-title":"Screening potential therapies: Lessons learned from new paradigms used in Parkinson disease","volume":"38","author":"Tilley","year":"2007","journal-title":"Stroke"},{"key":"10.3233\/JPD-191856_ref14","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/01.WNL.0000058760.13152.1A","article-title":"Neuroprotective agents for clinical trials in Parkinson\u2019s disease: A systematic assessment","volume":"60","author":"Ravina","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JPD-191856_ref15","doi-asserted-by":"crossref","first-page":"e021944","DOI":"10.1136\/bmjopen-2018-021944","article-title":"Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): A multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis","volume":"8","author":"Connick","year":"2018","journal-title":"BMJ Open"},{"key":"10.3233\/JPD-191856_ref16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s004150050560","article-title":"Placebo effect in the acute treatment of migraine: Subcutaneous placebos are better than oral placebos","volume":"247","author":"de Craen","year":"2000","journal-title":"J Neurol"},{"key":"10.3233\/JPD-191856_ref17","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/acn3.412","article-title":"A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III)","volume":"4","author":"Biglan","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.3233\/JPD-191856_ref19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jamaneurol.2014.131","article-title":"A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease","volume":"71","author":"Beal","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-191856_ref20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1545968311421614","article-title":"Disease randomized controlled trial of community-based dancing to modify disease progression in Parkinson","volume":"26","author":"Duncan","year":"2012","journal-title":"Neurorehabil Neural Repair"},{"key":"10.3233\/JPD-191856_ref21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N Engl J Med"},{"key":"10.3233\/JPD-191856_ref23","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jama.2015.120","article-title":"Effect of creatine monohydrate on clinical progression in patients with parkinson disease: A randomized clinical trial","volume":"313","author":"Kieburtz","year":"2015","journal-title":"JAMA"},{"key":"10.3233\/JPD-191856_ref24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1474-4422(13)70117-0","article-title":"Pramipexole in patients with early Parkinson\u2019s disease (PROUD): A randomised delayed-start trial","volume":"12","author":"Schapira","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-191856_ref25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJMoa1809983","article-title":"Randomized delayed-start trial of levodopa in Parkinson\u2019s disease","volume":"380","author":"Verschuur","year":"2019","journal-title":"N Engl J Med"},{"key":"10.3233\/JPD-191856_ref26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mdc3.12553","article-title":"Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson\u2019s Progression Markers Initiative Cohort","volume":"5","author":"Holden","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JPD-191856_ref27","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/mds.27303","article-title":"Are the MDS-UPDRS-based composite scores clinically applicable?","volume":"33","author":"Makkos","year":"2018","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/mds.21429","article-title":"Rate of clinical progression in Parkinson\u2019s disease. A prospective study","volume":"22","author":"Schrag","year":"2007","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref29","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mds.26960","article-title":"Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson\u2019s disease rating scale","volume":"32","author":"Horv\u00e1th","year":"2017","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref30","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/mds.27790","article-title":"Measuring Parkinson\u2019s disease over time: The real-world within-subject reliability of the MDS-UPDRS","volume":"34","author":"Evers","year":"2019","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1208\/s12248-009-9123-2","article-title":"Endpoints and analyses to discern disease-modifying drug effects in early Parkinson\u2019s disease","volume":"11","author":"Bhattaram","year":"2009","journal-title":"AAPS J"},{"key":"10.3233\/JPD-191856_ref32","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1474-4422(09)70291-1","article-title":"Progression of Parkinson\u2019s disease in the clinical phase: Potential markers","volume":"8","author":"Maetzler","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-191856_ref33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10928-006-9012-6","article-title":"Disease progression and pharmacodynamics in Parkinson disease \u2013 evidence for functional protection with levodopa and other treatments","volume":"33","author":"Holford","year":"2006","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.3233\/JPD-191856_ref34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mds.26644","article-title":"A review of disease progression models of Parkinson\u2019s disease and applications in clinical trials","volume":"31","author":"Venuto","year":"2016","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref35","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1474-4422(17)30328-9","article-title":"Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson\u2019s disease: A longitudinal cohort study and validation","volume":"16","author":"Latourelle","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-191856_ref36","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JPD-181306","article-title":"Progression of cognitive decline in Parkinson\u2019s disease","volume":"8","author":"Roheger","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-191856_ref37","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/jnnp-2016-315099","article-title":"Stability of mild cognitive impairment in newly diagnosed Parkinson\u2019s disease","volume":"88","author":"Lawson","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-191856_ref38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mds.23416","article-title":"Nonlinear decline of Mini-Mental State Examination in Parkinson\u2019s disease","volume":"26","author":"Aarsland","year":"2011","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2125.2012.04192.x","article-title":"Progression of motor and nonmotor features of Parkinson\u2019s disease and their response to treatment","volume":"74","author":"Vu","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.3233\/JPD-191856_ref40","first-page":"1","article-title":"Responsiveness to change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in non-demented patients with Parkinson\u2019s disease","volume":"17","author":"Faust-Socher","year":"2019","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JPD-191856_ref41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12883-016-0606-3","article-title":"A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"16","author":"McGhee","year":"2016","journal-title":"BMC Neurol"},{"key":"10.3233\/JPD-191856_ref42","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1007\/s00415-017-8620-y","article-title":"Natural history of falls in an incident cohort of Parkinson\u2019s disease: Early evolution, risk and protective features","volume":"264","author":"Lord","year":"2017","journal-title":"J Neurol"},{"key":"10.3233\/JPD-191856_ref43","doi-asserted-by":"crossref","first-page":"E2045","DOI":"10.1212\/WNL.0000000000006576","article-title":"Early predictors of mortality in parkinsonism and Parkinson disease A population-based study","volume":"91","author":"B\u00e4ckstr\u00f6m","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JPD-191856_ref44","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/jnnp.2006.100107","article-title":"Estimated life expectancy of Parkinson\u2019s patients compared with the UK population","volume":"78","author":"Ishihara","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-191856_ref45","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archneur.60.1.91","article-title":"Survival study of Parkinson disease in Olmsted County, Minnesota","volume":"60","author":"Elbaz","year":"2003","journal-title":"Arch Neurol"},{"key":"10.3233\/JPD-191856_ref46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jnnp.67.3.300","article-title":"The Sydney multicentre study of Parkinson\u2019s disease: Progression and mortality at 10 years","volume":"67","author":"Hely","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-191856_ref47","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/jnnp.60.5.592-a","article-title":"Further evidence of increased risk of mortality from Parkinson\u2019s disease","volume":"60","author":"Tison","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-191856_ref48","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1212\/01.WNL.0000115116.56955.50","article-title":"Mortality and Parkinson disease: A community based study","volume":"62","author":"Herlofson","year":"2004","journal-title":"Neurology"},{"key":"10.3233\/JPD-191856_ref49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/01.WNL.0000148603.44618.19","article-title":"Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort","volume":"64","author":"Marras","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JPD-191856_ref50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp-2017-316213","article-title":"Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson\u2019s disease: The PPMI cohort","volume":"89","author":"Simuni","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-191856_ref51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ene.12165","article-title":"Assessing the non-motor symptoms of Parkinson\u2019s disease: MDS-UPDRS and NMS Scale","volume":"22","author":"Martinez-Martin","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.3233\/JPD-191856_ref52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/mdc3.12728","article-title":"Pilot study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS)","volume":"6","author":"Martinez-Martin","year":"2019","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JPD-191856_ref53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17925\/ENR.2014.09.01.12","article-title":"Movement Disorders Parkinson\u2019s disease quality of life in Parkinson\u2019s disease-patient, clinical and research perspectives","volume":"9","author":"Stocchi","year":"2014","journal-title":"Eur Neurol Rev"},{"key":"10.3233\/JPD-191856_ref54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.17925\/ENR.2014.09.01.19","article-title":"Effect of therapeutic interventions on health-related quality of life in parkinson\u2019s disease","volume":"9","author":"Reichmann","year":"2014","journal-title":"Eur Neurol Rev"},{"key":"10.3233\/JPD-191856_ref55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework","volume":"69","author":"The Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.3233\/JPD-191856_ref56","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bpa.12370","article-title":"Alpha-synuclein as a biomarker for Parkinson\u2019s disease","volume":"26","author":"Atik","year":"2016","journal-title":"Brain Pathol"},{"key":"10.3233\/JPD-191856_ref57","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.metabol.2014.10.030","article-title":"Biomarkers of Parkinson\u2019s disease: Present and future","volume":"64","author":"Miller","year":"2015","journal-title":"Metabolism"},{"key":"10.3233\/JPD-191856_ref58","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"key":"10.3233\/JPD-191856_ref59","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/JPD-191576","article-title":"Extended treatment with glial cell line-derived neurotrophic factor in Parkinson\u2019s disease","volume":"9","author":"Whone","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-191856_ref60","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2015.06.028","article-title":"GM1 ganglioside in Parkinson\u2019s disease: Pilot study of effects on dopamine transporter binding","volume":"356","author":"Schneider","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.3233\/JPD-191856_ref61","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: A double-blind, randomised, controlled trial","volume":"9","author":"Marks","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-191856_ref62","doi-asserted-by":"crossref","first-page":"e0158235","DOI":"10.1371\/journal.pone.0158235","article-title":"Bee venom for the treatment of Parkinson disease - a randomized controlled clinical trial","volume":"11","author":"Hartmann","year":"2016","journal-title":"PLoS One"},{"key":"10.3233\/JPD-191856_ref63","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/brain\/awv184","article-title":"Effect of the myeloperoxidase inhibitor AZD3241 on microglia: A PET study in Parkinson\u2019s disease","volume":"138","author":"Jucaite","year":"2015","journal-title":"Brain"},{"key":"10.3233\/JPD-191856_ref64","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/ene.13474","article-title":"High-dose transdermal nicotine in Parkinson\u2019s disease patients: A randomized, open-label, blinded-endpoint evaluation phase 2 study","volume":"25","author":"Villafane","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.3233\/JPD-191856_ref65","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","article-title":"Pioglitazone in early Parkinson\u2019s disease: A phase 2, multicentre, double-blind, randomised trial","volume":"14","author":"Simuni","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-191856_ref66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12883-019-1252-3","article-title":"Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: Protocol for a single-centre, randomized, double-blind, placebo-controlled trial","volume":"19","author":"Silveira","year":"2019","journal-title":"BMC Neurol."},{"key":"10.3233\/JPD-191856_ref67","doi-asserted-by":"crossref","first-page":"e00470","DOI":"10.1002\/prp2.470","article-title":"Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson\u2019s disease","volume":"7","author":"Pagan","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.3233\/JPD-191856_ref68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40035-017-0076-6","article-title":"Imaging biomarkers in Parkinson\u2019s disease and Parkinsonian syndromes: Current and emerging concepts","volume":"6","author":"Saeed","year":"2017","journal-title":"Transl Neurodegener"},{"key":"10.3233\/JPD-191856_ref69","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/mds.27376","article-title":"Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson\u2019s disease clinical trial","volume":"33","author":"Lipsmeier","year":"2018","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref70","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.2196\/resprot.5990","article-title":"Large-scale wearable sensor deployment in Parkinson\u2019s patients: The Parkinson@Home Study Protocol","volume":"5","author":"L\u00edgia Silva de Lima","year":"2016","journal-title":"JMIR Res Protoc"},{"key":"10.3233\/JPD-191856_ref71","doi-asserted-by":"crossref","first-page":"160011","DOI":"10.1038\/sdata.2016.11","article-title":"The mPower study, Parkinson disease mobile data collected using ResearchKit","volume":"3","author":"Bot","year":"2016","journal-title":"Sci. Data"},{"key":"10.3233\/JPD-191856_ref72","doi-asserted-by":"crossref","first-page":"e0189161","DOI":"10.1371\/journal.pone.0189161","article-title":"Feasibility of large-scale deployment of multiple wearable sensors in Parkinson\u2019s disease","volume":"12","author":"L\u00edgia Silva de Lima","year":"2017","journal-title":"PLoS One"},{"key":"10.3233\/JPD-191856_ref74","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1474-4422(06)70349-0","article-title":"The measurement and clinical relevance of brain atrophy in multiple sclerosis","volume":"5","author":"Bermel","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-191856_ref75","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","article-title":"Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial","volume":"383","author":"Chataway","year":"2014","journal-title":"Lancet"},{"key":"10.3233\/JPD-191856_ref76","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1474-4422(14)70264-9","article-title":"Clinical trials in progressive multiple sclerosis: Lessons learned and future perspectives","volume":"14","author":"Ontaneda","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-191856_ref77","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/brain\/122.5.871","article-title":"Development of a multiple sclerosis functional composite as a clinical trial outcome measure","volume":"122","author":"Cutter","year":"1999","journal-title":"Brain"},{"key":"10.3233\/JPD-191856_ref78","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40263-016-0340-9","article-title":"Secondary progressive multiple sclerosis: Definition and measurement","volume":"30","author":"Plantone","year":"2016","journal-title":"CNS Drugs"},{"key":"10.3233\/JPD-191856_ref79","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","article-title":"Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Lublin","year":"2016","journal-title":"Lancet"},{"key":"10.3233\/JPD-191856_ref80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.3233\/JPD-191856_ref81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/17482960600888156","article-title":"Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Amyotroph Lateral Scler"},{"key":"10.3233\/JPD-191856_ref82","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/archneur.1996.00550020045014","article-title":"The Amyotrophic Lateral Sclerosis Functional Rating Scale","volume":"53","author":"The ALS CNTF Study Group","year":"1996","journal-title":"Arch Neurol"},{"key":"10.3233\/JPD-191856_ref83","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/21678421.2012.762930","article-title":"The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials","volume":"14","author":"Berry","year":"2013","journal-title":"Amyotroph Lateral Scler Front Degener"},{"key":"10.3233\/JPD-191856_ref84","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"10.3233\/JPD-191856_ref85","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.parkreldis.2015.05.022","article-title":"Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson\u2019s disease","volume":"21","author":"Yoritaka","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-191856_ref86","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/jnnp-2018-318337","article-title":"Developing and validating Parkinson\u2019s disease subtypes and their motor and cognitive progression","volume":"89","author":"Lawton","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-191856_ref87","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/brain\/awx118","article-title":"Clinical criteria for subtyping Parkinson\u2019s disease: Biomarkers and longitudinal progression","volume":"140","author":"Fereshtehnejad","year":"2017","journal-title":"Brain"},{"key":"10.3233\/JPD-191856_ref88","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamaneurol.2015.0703","article-title":"New clinical subtypes of Parkinson disease and their longitudinal progression","volume":"72","author":"Fereshtehnejad","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-191856_ref89","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","article-title":"Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: A cohort study","volume":"16","author":"Schrag","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JPD-191856_ref90","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/mds.27492","article-title":"Baseline predictors for progression 4 years after Parkinson\u2019s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref91","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1212\/WNL.0000000000002437","article-title":"Development and external validation of a prognostic model in newly diagnosed Parkinson disease","volume":"86","author":"Velseboer","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JPD-191856_ref92","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.parkreldis.2018.07.009","article-title":"Reproducibility of data-driven Parkinson\u2019s disease subtypes for clinical research","volume":"56","author":"Mestre","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-191856_ref93","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.parkreldis.2016.04.027","article-title":"How stable are Parkinson\u2019s disease subtypes in de novo patients: Analysis of the PPMI cohort?","volume":"28","author":"Simuni","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-191856_ref94","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/jnnp.2003.033530","article-title":"Heterogeneity of Parkinson\u2019s disease in the early clinical stages using a data driven approach","volume":"76","author":"Lewis","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-191856_ref95","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.parkreldis.2008.09.003","article-title":"The association between motor subtypes and psychopathology in Parkinson\u2019s disease","volume":"15","author":"Reijnders","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-191856_ref96","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1631\/jzus.B1100069","article-title":"Clinical heterogeneity in patients with early-stage Parkinson\u2019s disease: A cluster analysis","volume":"12","author":"Liu","year":"2011","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.3233\/JPD-191856_ref97","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/jnnp.52.6.718","article-title":"Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson\u2019s disease","volume":"52","author":"Kempster","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-191856_ref98","first-page":"231","article-title":"L-dopa therapy of Parkinson\u2019s disease: Plasma L-dopa concentration, therapeutic response, and side effects","volume":"46","author":"Muenter","year":"1971","journal-title":"Mayo Clin Proc"},{"key":"10.3233\/JPD-191856_ref99","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson\u2019s disease","volume":"351","author":"The Parkinson Study Group","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3233\/JPD-191856_ref100","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/mds.10226","article-title":"Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson\u2019s disease","volume":"17","author":"Hauser","year":"2002","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191856_ref101","first-page":"419","article-title":"A new look at levodopa based on the ELLDOPA study","volume":"70","author":"Fahn","year":"2006","journal-title":"J Neural Transm"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-191856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:47:28Z","timestamp":1777610848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-191856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":97,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jpd-191856","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]}}}